Recent clinical trials have shown highly promising responses in a subset of patients treated with immune checkpoint inhibitory anti-programmed cell death-1, anti-programmed cell death ligand-1 (PD-1), and anticytotoxic T-lymphocyte-associated antigen-4 antibodies (CTLA-4) [1] [2] [3] [4] . However, immunotherapy against poorly immunogenic cancers remains a challenge. Large, modestly immunogenic CT26 tumors or poorly immunogenic metastatic 4T1 tumors in mice were unresponsive to anti-PD-1 and anti-CTLA-4 treatments. Cotreatment with DNA methyltransferase and HDAC inhibitors, and checkpoint inhibitors markedly improved treatment outcomes, curing more than 80% of the tumor-bearing mice. Functional studies revealed that the primary targets of the epigenetic modulators were myeloid-derived suppressor cells (MDSCs). In addition, reduction of MDSCs using antibodies directed against them or a PI3K inhibitor that reduced circulating MDSCs had similar antitumor effects to those observed with the epigenetic modulators. Our results show that elevated myeloid-derived suppressor cells (MDSCs) are responsible for the resistance to checkpoint inhibitors and that elimination of MDSCs can lead to cures of experimental, metastatic tumors. 
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